Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONNASDAQ:GNLXNASDAQ:HCATNASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.87+0.5%$1.93$1.60▼$2.54$717.37M1.041.35 million shs1.57 million shsGNLXGenelux$2.77-6.7%$2.67$1.60▼$5.89$112.07M-0.49191,001 shs98,839 shsHCATHealth Catalyst$3.74+3.9%$3.92$3.49▼$9.24$250.56M1.53608,903 shs575,339 shsNVAXNovavax$6.31-1.6%$6.74$5.01▼$17.81$1.04B2.816.38 million shs3.73 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%-3.63%-8.37%-1.06%-20.17%GNLXGenelux0.00%-2.94%+15.12%-23.65%+44.17%HCATHealth Catalyst0.00%-5.26%-1.37%-19.28%-41.27%NVAXNovavax0.00%-7.64%-11.59%-16.64%-54.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.5863 of 5 stars0.05.00.00.00.60.02.5GNLXGenelux0.7307 of 5 stars3.60.00.00.00.00.00.0HCATHealth Catalyst4.4096 of 5 stars4.32.00.03.80.92.51.3NVAXNovavax4.3991 of 5 stars3.12.00.04.71.30.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AGNLXGenelux 3.20Buy$17.75540.79% UpsideHCATHealth Catalyst 2.64Moderate Buy$8.00113.90% UpsideNVAXNovavax 2.29Hold$17.00169.41% UpsideCurrent Analyst Ratings BreakdownLatest HCAT, CRON, GNLX, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025HCATHealth CatalystBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral6/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.005/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.005/8/2025HCATHealth CatalystCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $9.005/8/2025HCATHealth CatalystStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$5.00 ➝ $5.504/25/2025HCATHealth CatalystCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.504/16/2025HCATHealth CatalystKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$7.00 ➝ $5.004/9/2025HCATHealth CatalystEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/9/2025HCATHealth CatalystEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ In-Line$6.00 ➝ $4.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.61M6.13N/AN/A$2.90 per share0.64GNLXGenelux$10K10,453.98N/AN/A$0.76 per share3.64HCATHealth Catalyst$306.58M0.85$0.37 per share10.21$6.00 per share0.62NVAXNovavax$682.16M1.50N/AN/A($3.89) per share-1.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.1314.3962.3342.1839.69%-0.07%-0.07%8/6/2025 (Estimated)GNLXGenelux-$29.87M-$0.88N/AN/AN/AN/A-93.04%-74.17%8/13/2025 (Estimated)HCATHealth Catalyst-$69.50M-$1.15N/AN/AN/A-23.34%-6.14%-2.74%8/6/2025 (Estimated)NVAXNovavax-$187.50M$2.652.3878.880.0738.14%-115.51%29.99%8/14/2025 (Estimated)Latest HCAT, CRON, GNLX, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AHCATHealth CatalystN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A27.8026.75GNLXGeneluxN/A4.674.67HCATHealth Catalyst0.401.241.24NVAXNovavaxN/A2.062.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%GNLXGenelux37.33%HCATHealth Catalyst85.00%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCRONCronos Group6.90%GNLXGenelux9.30%HCATHealth Catalyst2.60%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.68 million359.07 millionOptionableGNLXGenelux1037.74 million34.23 millionNot OptionableHCATHealth Catalyst1,50069.60 million67.79 millionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableHCAT, CRON, GNLX, and NVAX HeadlinesRecent News About These CompaniesNotable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focusJune 22 at 11:02 AM | msn.comNovavax Faces Challenges Amid Stock DeclineJune 21 at 10:23 AM | tipranks.comNovavax (NVAX) Ascends While Market Falls: Some Facts to NoteJune 20 at 6:46 PM | zacks.comBrokerages Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $19.20June 20 at 1:37 AM | americanbankingnews.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowJune 19, 2025 | zacks.comNovavax slips as Citi launches with Sell rating on pipeline concernsJune 17, 2025 | seekingalpha.comNovavax slips as Citi launches with Sell rating on pipeline concernsJune 17, 2025 | msn.comNovavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?June 17, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Earns Sell Rating from Analysts at CitigroupJune 17, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 17, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)June 14, 2025 | theglobeandmail.comNovavax: New Vaccine, Same Old Story - Still A SellJune 13, 2025 | seekingalpha.comNovavax, Inc. (NASDAQ:NVAX) Shares Sold by SG Americas Securities LLCJune 13, 2025 | marketbeat.comNovavax's COVID-Flu Combo Shot Shows Strong Immune ResponseJune 12, 2025 | zacks.comNovavax's COVID-flu combo vaccine shows strong immune response in trialJune 12, 2025 | msn.comNovavax preps late-stage trial as COVID-flu combo vaccine matches rivalsJune 12, 2025 | thepharmaletter.comNovavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptJune 11, 2025 | seekingalpha.comNovavax’s COVID-flu combo vaccine shows strong immune responseJune 11, 2025 | msn.comTesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fallJune 11, 2025 | investing.comNovavax posts immune data to back COVID-flu combo shot and standalone flu shotJune 11, 2025 | msn.comNovavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine CandidatesJune 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment HCAT, CRON, GNLX, and NVAX Company DescriptionsCronos Group NASDAQ:CRON$1.87 +0.01 (+0.54%) Closing price 04:00 PM EasternExtended Trading$1.88 +0.01 (+0.48%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Genelux NASDAQ:GNLX$2.77 -0.20 (-6.73%) Closing price 04:00 PM EasternExtended Trading$2.86 +0.09 (+3.25%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Health Catalyst NASDAQ:HCAT$3.74 +0.14 (+3.89%) Closing price 04:00 PM EasternExtended Trading$3.74 +0.00 (+0.13%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.Novavax NASDAQ:NVAX$6.31 -0.10 (-1.56%) Closing price 04:00 PM EasternExtended Trading$6.34 +0.03 (+0.48%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
